Upgrade to SI Premium - Free Trial

Biogen (BIIB) PT Lowered to $344 at Stifel

October 14, 2021 5:11 PM
Stifel analyst Paul Matteis lowered the price target on Biogen (NASDAQ: BIIB) to $344.00 (from $430.00) while maintaining a Buy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change

Next Articles